NASDAQIndustrialsConglomeratesSnapshot 2026-07-23
Reading HHS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a turnaround investment thesis. HHS is currently loss-making and has shown mixed management effectiveness, with a focus on deepening customer relationships and achieving positive EBITDA.
The market appears to have priced in a justified valuation, reflecting its cheapness compared to peers. However, there is a notable expectations gap, indicating that investors may anticipate further challenges ahead.
Fundamentals are likely to remain under pressure in the near term, given the elevated risk of missing earnings expectations. Recent financial performance has been weak, and the company has a history of consecutive earnings misses.
The thesis hinges on the performance of sector bellwethers like MMM, HON, and VMI. If these companies continue to perform well, it could provide a favorable backdrop for HHS. Conversely, any guidance cuts or misses from these peers could negatively impact HHS.
Over the next 1 to 3 years, HHS will need to navigate significant challenges while seeking to improve its financial standing. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The net income results will show if the company can stay profitable after Q1 loss.
Confirms:Q2 2026 net income shows a profit after the Q1 loss.
Disproves:Q2 2026 net income shows a loss greater than $0.63M.
Why it matters: A bigger drop in revenue shows problems with old products and market challenges.
Confirms:Q2 2026 revenue reported down more than 10% year over year.
Disproves:Q2 2026 revenue stabilizes or grows year over year.
Why it matters: Sector growth impacts Harte Hanks' ability to improve its performance.
Confirms one read:Sector revenue growth speeds up to 5% or more in Q3 2026.
Confirms the other:Sector revenue growth remains below 5% in Q3 2026.
Why it matters: Positive EBITDA means better cost control. This leads to making more money.
Confirms:Q2 2026 EBITDA was over $0 million.
Disproves:Q2 2026 EBITDA is still negative.
Why it matters: New business wins would support growth and validate the shift to higher-value services.
Confirms:Announcement of at least two new significant contracts in key sectors.
Disproves:No new strategic contracts announced in Q2 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
